COVID-19 in patients with rheumatic diseases: what is the real mortality risk?

Marques, Claudia; Pinheiro, Marcelo M; Reis Neto, Edgard Torres; Dantas, Andrea Tavares; Ribeiro, Francinne Machado; Melo, Ana Karla G

Marques, Claudia; Pinheiro, Marcelo M; Reis Neto, Edgard Torres; Dantas, Andrea Tavares; Ribeiro, Francinne Machado; Melo, Ana Karla G.

Marques C; Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil claudia.reumatologia@gmail.com.
Pinheiro MM; Hospital São Paulo, Universidade Federal de São Paulo, São Paulo, Brazil.
Reis Neto ET; Hospital São Paulo, Universidade Federal de São Paulo, São Paulo, Brazil.
Dantas AT; Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil.
Ribeiro FM; Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Melo AKG; Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, Joao Pessoa, Brazil.

Ann Rheum Dis ; 81(8): e134, 2022 08.

Article in English | MEDLINE | ID: covidwho-2309792

Subject(s)

Autoimmune Diseases; COVID-19; Lupus Erythematosus, Systemic; Rheumatic Diseases; Humans; Rheumatic Diseases/complications

Keywords

autoimmune diseases; glucocorticoids; lupus erythematosus, systemic

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Rheumatic Diseases / COVID-19 / Lupus Erythematosus, Systemic Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2022 Document Type: Article Affiliation country: Annrheumdis-2020-218388

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google